Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Psilocybin as a new way for depression treatment
  • Home
  • /
  • Psilocybin as a new way for depression treatment
  1. Home /
  2. Archives /
  3. Vol. 68 (2024) /
  4. Medical Sciences

Psilocybin as a new way for depression treatment

Authors

  • Mateusz Maciej Pawlicki Medical University of Lublin https://orcid.org/0000-0001-8318-6573
  • Aleksandra Kłos Student Scientific Association at Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, ul. Radziwiłłowska 11, Lublin 20-080, Poland https://orcid.org/0009-0008-6870-2590
  • Karol Stachyrak Independent Public Health Care Center in Łęczna, Krasnystawska 52 street, 21-010 Łęczna, Poland https://orcid.org/0009-0008-3175-1866
  • Dawid Mika 1st Military Clinical Hospital with SPZOZ Polyclinic in Lublin, Racławickie 23 avenue, 20-049 Lublin, Poland https://orcid.org/0009-0003-5254-5344
  • Bartosz Mazur Kardynał Stefan Wyszyński Province Specialist Hospital in Lublin, Kraśnicka 100 avenue, 20-718 Lublin, Poland https://orcid.org/0000-0003-0601-4350
  • Kamila Turek Student Scientific Association at Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, ul. Radziwiłłowska 11, Lublin 20-080, Poland https://orcid.org/0009-0000-6888-8913
  • Maciej Lambach Kardynał Stefan Wyszyński Province Specialist Hospital in Lublin, Kraśnicka 100 avenue, 20-718 Lublin, Poland https://orcid.org/0009-0004-3348-4272
  • Anna Greguła Independent Public Health Care Center in Łęczna, Krasnystawska 52 street, 21-010 Łęczna, Poland https://orcid.org/0009-0007-3712-7960
  • Aleksandra Mazurek Student Scientific Association at Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, ul. Radziwiłłowska 11, Lublin 20-080, Poland https://orcid.org/0009-0007-5298-782X
  • Wiktoria Wilanowska Kardynał Stefan Wyszyński Province Specialist Hospital in Lublin, Kraśnicka 100 avenue, 20-718 Lublin, Poland https://orcid.org/0009-0000-8388-8479

DOI:

https://doi.org/10.12775/JEHS.2024.68.50168

Keywords

psilocybin, depression

Abstract

Introduction: Mental disorders are common and still growing problem around the globe. Significantly decreasing quality of life, they are often source of true suffering for patients and their families leading to further health issues or even dramatic outcomes resulting in death. As public awareness rises, more and more people understand risks and tend to look for help as fast as possible. Currently available treatment methods are not always efficient enough to deal with more complex cases. Therefore it is important to look for new therapy options incrementing chances of fast and successful treatment.

Results: Studies showed that psilocybin is not only able to lower depression and anxiety scores in patients with major depressive disorders or with serious life-threatening conditions but also proved this effect to be long-lasting. At the same time, no or little adverse side effects were noticed.

Conclusions: Psilocybin is potentially a good method for depression treatment in some groups of patients. It should be considered if other, better known therapies show little or no effects.

References

Mental disorders [Internet]. [cited 2022 Sep 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/mental-disorders

Roser M, Ritchie H. Burden of Disease. Our World in Data. 2021 Sep 25;

Prevalence by mental and substance use disorder, World, 2019 [Internet]. [cited 2022 Sep 18]. Available from: https://ourworldindata.org/grapher/prevalence-by-mental-and-substance-use-disorder?time=latest

Zhou Y, Rosenheck R, Mohamed S, Ou Y, Ning Y, He H. Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China. BMC Psychiatry [Internet]. 2016 Aug 11 [cited 2024 Mar 19];16(1). Available from: /pmc/articles/PMC4980784/

Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry [Internet]. 2014 Oct 1 [cited 2024 Apr 1];1(5):343–50. Available from: https://pubmed.ncbi.nlm.nih.gov/26360998/

Tsaras K, Papathanasiou I V., Mitsi D, Veneti A, Kelesi M, Zyga S, et al. Assessment of Depression and Anxiety in Breast Cancer Patients: Prevalence and Associated Factors. Asian Pac J Cancer Prev [Internet]. 2018 Jun 1 [cited 2024 Apr 1];19(6):1661. Available from: /pmc/articles/PMC6103579/

Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017 Jan 15;372:331–41.

Siegmann EM, Müller HHO, Luecke C, Philipsen A, Kornhuber J, Grömer TW. Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis. JAMA Psychiatry [Internet]. 2018 Jun 1 [cited 2024 Apr 1];75(6):577. Available from: /pmc/articles/PMC6137529/

Pandarakalam JP. Challenges of Treatment-resistant Depression. Psychiatr Danub [Internet]. 2018 [cited 2024 Apr 1];30(3):273–84. Available from: https://pubmed.ncbi.nlm.nih.gov/30267518/

Nuñez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord [Internet]. 2022 Apr 1 [cited 2024 Apr 1];302:385–400. Available from: https://pubmed.ncbi.nlm.nih.gov/34986373/

Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019 May 1;197:83–102.

Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The Therapeutic Potential of Psilocybin. Molecules 2021, Vol 26, Page 2948 [Internet]. 2021 May 15 [cited 2024 Apr 1];26(10):2948. Available from: https://www.mdpi.com/1420-3049/26/10/2948/htm

Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addiction Biology. 2002 Oct;7(4):357–64.

Coppola M, Bevione F, Mondola R. Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective? J Xenobiot [Internet]. 2022 Mar 1 [cited 2024 Apr 2];12(1):41. Available from: /pmc/articles/PMC8883979/

Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, et al. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs 2021 36:1 [Internet]. 2021 Nov 17 [cited 2024 Mar 5];36(1):17–30. Available from: https://link.springer.com/article/10.1007/s40263-021-00877-y

Goel DB, Zilate S. Potential Therapeutic Effects of Psilocybin: A Systematic Review. Cureus [Internet]. 2022 Oct 12 [cited 2024 Apr 2];14(10). Available from: /pmc/articles/PMC9650681/

Tylš F, Páleníček T, Horáček J. Psilocybin - Summary of knowledge and new perspectives. European Neuropsychopharmacology. 2014 Mar;24(3):342–56.

Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction [Internet]. 2004 Jun 1 [cited 2024 Apr 1];99(6):686–96. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1360-0443.2004.00744.x

Leary T, Litwin GH, Metzner R. Reactions to psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease. 1963;137(6):561–73.

Timothy L, Ralph M, Madison P, Gunther W, Ralph S, Sara K. A new behavior change program using psilocybin. Psychotherapy: Theory, Research & Practice [Internet]. 1965 [cited 2022 Sep 22];2(2):61–72. Available from: /doiLanding?doi=10.1037%2Fh0088612

Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016 Jul 1;3(7):619–27.

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018 Feb 1;235(2):399–408.

Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine [Internet]. 2022 Nov 3 [cited 2024 Mar 6];387(18):1637–48. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2206443

Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology [Internet]. 2023 Sep 1 [cited 2024 Mar 6];48(10):1492. Available from: /pmc/articles/PMC10425429/

Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA [Internet]. 2023 Sep 5 [cited 2024 Mar 6];330(9):843–53. Available from: https://jamanetwork.com/journals/jama/fullarticle/2808950

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021 May 1;78(5):481–9.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology. 2016 Dec 1;30(12):1181–97.

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology. 2016 Dec 1;30(12):1165–80.

Agrawal M, Richards W, Beaussant Y, Shnayder S, Ameli R, Roddy K, et al. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. 2023;

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. 2021 Apr 15;384(15):1402–11.

Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology [Internet]. 2022 Feb 1 [cited 2024 Mar 6];36(2):151–8. Available from: https://journals.sagepub.com/doi/full/10.1177/02698811211073759?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org

Downloads

  • PDF

Published

2024-05-15

How to Cite

1.
PAWLICKI, Mateusz Maciej, KŁOS, Aleksandra, STACHYRAK, Karol, MIKA, Dawid, MAZUR, Bartosz, TUREK, Kamila, LAMBACH, Maciej, GREGUŁA, Anna, MAZUREK, Aleksandra and WILANOWSKA, Wiktoria. Psilocybin as a new way for depression treatment. Journal of Education, Health and Sport. Online. 15 May 2024. Vol. 68, p. 50168. [Accessed 8 July 2025]. DOI 10.12775/JEHS.2024.68.50168.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 68 (2024)

Section

Medical Sciences

License

Copyright (c) 2024 Mateusz Maciej Pawlicki, Aleksandra Kłos, Karol Stachyrak, Dawid Mika, Bartosz Mazur, Kamila Turek, Maciej Lambach, Anna Greguła, Aleksandra Mazurek, Wiktoria Wilanowska

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 337
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

psilocybin, depression
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop